ALOX15

15-lipoxygenase

Score: 0.547 Price: $0.55 Low Druggability Status: active Wiki: ALOX15

🧠 Neurodegeneration

HYPOTHESES

3

PAPERS

31

KG EDGES

207

DEBATES

1

3D Protein Structure

🧬 ALOX15 — PDB 4NRE Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.38

Clinical Stage

Approved

Target Class

Enzyme

Safety

0.60

Druggability Analysis

Drug Development0.75

Structural Tractability0.30

Target Class0.85

Safety Profile0.60

Key Metrics

PDB Structures:

0

Known Drugs:

2

Approved:

1

In Clinical Trials:

0

Drug Pipeline (2 compounds)

1 Approved · 1 Preclinical

Druggability Rationale: This enzyme has moderate druggability. The active site may be partially accessible, or substrate mimicry approaches may face selectivity challenges against related family members. AlphaFold predicted structure available for computational screening. 1 approved drug(s) validate this target pharmacologically.

Mechanism: Small molecule inhibitors targeting the active site iron and substrate binding

Drug Pipeline (2 compounds)

1 Approved · 1 Preclinical

Known Drugs:

Zileuton (approved) — Asthma

PD146176 (preclinical) — Inflammation

Structural Data:

PDB —AlphaFold ✓Cryo-EM —

UniProt: P16050

🧬 3D Protein Structure

🧬 ALOX15 — PDB 4NRE Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity within the enzyme family is important to avoid mechanism-based toxicity. Isoform-selective inhibitors generally have superior therapeutic windows.

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for P16050

View AlphaFold Structure

Clinical Trials (7)

Relevant trials from ClinicalTrials.gov

Active

0

Completed

6

Total Enrollment

302

By Phase

PHASE1: 3 · PHASE2: 2 · PHASE4: 2

Single Dose Bronchodilatory Study in Asthma Completed

PHASE4 NCT01805687 n=25

Asthma

Interventions: Zileuton extended release

Sponsor: Cornerstone Therapeutics Inc. | Started: 2013-03

Zileuton and Exhaled Nitric Oxide in Asthmatics Completed

PHASE4 NCT00575861 n=19

Asthma

Interventions: zileuton

Sponsor: Gelb, Arthur F., M.D. | Started: 2005-09

PF-04191834 Single Dose Bronchodilatory Study In Asthma. Completed

PHASE2 NCT00723021 n=15

Asthma

Interventions: PF-04191834, PF-04191834, PF-04191834

Sponsor: Pfizer | Started: 2008-07

Safety Study of Zileuton Injection in Patients With Asthma Completed

PHASE1 NCT00299065 n=60

Asthma

Interventions: Zileuton injection

Sponsor: Critical Therapeutics | Started: 2006-01

Trial of Zileuton CR in Children and Adults With Sickle Cell Disease Completed

PHASE1 NCT01136941 n=9

Sickle Cell Disease

Interventions: Zileuton

Sponsor: Children's Hospital Medical Center, Cincinnati | Started: 2010-09

Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers Completed

PHASE1 NCT01021215 n=84

Tobacco Use Disorder

Interventions: Zileuton, Celecoxib, laboratory biomarker analysis

Sponsor: National Cancer Institute (NCI) | Started: 2010-05

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris Unknown

PHASE2 NCT00098358 n=90

Acne Vulgaris

Interventions: Zileuton

Sponsor: Critical Therapeutics | Started: 2004-11

Linked Hypotheses (2)

ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE Peroxidation0.777

Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy0.695

Linked Experiments (1)

s:** - ALOX15 overexpression in healthy astrocytes should be protective if the hypothesis is correct0.400

Scoring Dimensions

Knowledge Graph (20)

activates (1)

associated with (2)

ALOX15→neurodegenerationLOX→ALOX15

co discussed (10)

BMAL1→ALOX15ALOX15→CLOCKALOX15→TFRCALOX15→GPR37ALOX15→CMKLR1

▸ Show 5 more

ALOX15→ALOX12ALOX15→ALOX5ALOX15→TREM2ALOX15→AADCALOX15→BCL2L1

contributes to (2)

ALOX5→ALOX15ALOX12→ALOX15

inhibits (5)

FASN→ALOX15BAX→ALOX15ALOX15→GSDMDALOX15→SCD1ALOX15→HMGCR

Debate History (1)

Should ALOX15 (15-lipoxygenase) be prioritized as a therapeutic target for neuro2026-04-22